DZ3438A1 - Inhibiteurs peptidomimetiques de protease - Google Patents
Inhibiteurs peptidomimetiques de proteaseInfo
- Publication number
- DZ3438A1 DZ3438A1 DZ013438A DZ013438A DZ3438A1 DZ 3438 A1 DZ3438 A1 DZ 3438A1 DZ 013438 A DZ013438 A DZ 013438A DZ 013438 A DZ013438 A DZ 013438A DZ 3438 A1 DZ3438 A1 DZ 3438A1
- Authority
- DZ
- Algeria
- Prior art keywords
- protease inhibitors
- peptidomimetic protease
- peptidomimetic
- inhibitors
- protease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22939800P | 2000-08-31 | 2000-08-31 | |
US27764101P | 2001-03-21 | 2001-03-21 | |
PCT/US2001/026008 WO2002018369A2 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimetiques de protease |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ3438A1 true DZ3438A1 (fr) | 2002-03-07 |
Family
ID=26923261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ013438A DZ3438A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimetiques de protease |
Country Status (37)
Country | Link |
---|---|
US (5) | US7820671B2 (fr) |
EP (9) | EP2368901A1 (fr) |
JP (4) | JP4689938B2 (fr) |
KR (10) | KR20080104383A (fr) |
CN (7) | CN101633636B (fr) |
AR (1) | AR030591A1 (fr) |
AT (2) | ATE431358T1 (fr) |
AU (2) | AU2001288318B2 (fr) |
BR (1) | BR0113666A (fr) |
CA (2) | CA2419607C (fr) |
CL (1) | CL2010000330A1 (fr) |
CY (2) | CY1109216T1 (fr) |
CZ (1) | CZ2003595A3 (fr) |
DE (4) | DE20122915U1 (fr) |
DK (2) | DK1878720T3 (fr) |
DZ (1) | DZ3438A1 (fr) |
EA (2) | EA011547B1 (fr) |
EC (2) | ECSP034493A (fr) |
ES (4) | ES2489115T3 (fr) |
HK (3) | HK1163061A1 (fr) |
HR (1) | HRP20030139B8 (fr) |
HU (1) | HUP0300855A3 (fr) |
IL (6) | IL154671A0 (fr) |
LU (1) | LU91960I2 (fr) |
MX (1) | MXPA03001780A (fr) |
NO (4) | NO329929B1 (fr) |
NZ (2) | NZ541302A (fr) |
PE (1) | PE20020474A1 (fr) |
PL (1) | PL211019B1 (fr) |
PT (1) | PT1320540E (fr) |
SI (1) | SI1320540T1 (fr) |
SK (1) | SK2492003A3 (fr) |
SV (1) | SV2003000617A (fr) |
TW (6) | TWI378927B (fr) |
UA (2) | UA81600C2 (fr) |
WO (1) | WO2002018369A2 (fr) |
ZA (1) | ZA200301641B (fr) |
Families Citing this family (237)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9712544B1 (pt) * | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
IL152022A0 (en) * | 2000-04-03 | 2003-04-10 | Vertex Pharma | Compounds useful as protease inhibitors and pharmaceutical compositions containing the same |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EP1294735A2 (fr) | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Procedes et compositions de traitement des flavivirus et des pestivirus |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
RU2003105221A (ru) | 2000-07-21 | 2004-09-20 | Шеринг Корпорейшн (US) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с |
AU2001276988B2 (en) | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
GB2368339B (en) | 2000-10-26 | 2002-09-18 | Yissum Res Dev Co | Complex incorporating a plurality of antioxidants |
MXPA04003825A (es) * | 2001-10-24 | 2004-07-08 | Vertex Pharma | Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado. |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
WO2003087092A2 (fr) | 2002-04-11 | 2003-10-23 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c |
ATE503764T1 (de) * | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
RS114004A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
AU2003277891A1 (en) * | 2002-09-23 | 2004-04-08 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
WO2004092161A1 (fr) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc |
WO2004092162A1 (fr) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc |
AU2011203054B2 (en) * | 2003-04-11 | 2012-04-26 | Vertex Pharmaceuticals, Incorporated | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
CN1791599A (zh) | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
EP2345661A1 (fr) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Analogues de nucléosides fluores modifiés |
UY28423A1 (es) | 2003-07-18 | 2005-02-28 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- |
MY148123A (en) * | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
AU2004272114B2 (en) * | 2003-09-12 | 2010-11-04 | Vertex Pharmaceuticals Incorporated | Animal model for protease activity and liver damage |
TW200526686A (en) | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
KR20060130027A (ko) | 2003-10-10 | 2006-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의억제제 |
CN1906208B (zh) * | 2003-10-10 | 2011-03-30 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
EP1944042A1 (fr) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinaisons pour le traitement HCV |
WO2005043118A2 (fr) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Methode de decouverte de medicament |
US7494660B2 (en) | 2003-10-27 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
MXPA06004723A (es) * | 2003-10-27 | 2006-07-05 | Vertex Pharma | Combinacion para el tratamiento del hcv. |
TW200518746A (en) | 2003-12-11 | 2005-06-16 | Schering Corp | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
AU2005212257A1 (en) * | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
NZ549223A (en) * | 2004-02-27 | 2010-10-29 | Schering Corp | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
KR20060124725A (ko) * | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | C형 간염 바이러스 ns3 프로테아제의 억제제 |
AU2005219824B2 (en) * | 2004-02-27 | 2007-11-29 | Merck Sharp & Dohme Corp. | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
WO2005087730A1 (fr) * | 2004-02-27 | 2005-09-22 | Schering Corporation | Composes de proline fusionnes a 3,4-(cyclopentyl) en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c |
US20060089385A1 (en) * | 2004-06-08 | 2006-04-27 | Yong Cui | Pharmaceutical compositions |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
CA2573346C (fr) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Analogues peptidiques inhibiteurs de l'hepatite c |
MX2007003812A (es) * | 2004-10-01 | 2007-05-24 | Vertex Pharma | Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc). |
MY141025A (en) | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
EA017874B1 (ru) | 2005-03-21 | 2013-03-29 | Вайробей, Инк. | Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз |
EP2047850A3 (fr) * | 2005-04-12 | 2009-07-29 | Romark Laboratories, L.C. | Procédés pour traiter des maladies avec composés qui inhibent la fonction molécules chaperonnes telles que des isomérases de disulfure protéiques, compositions pharmaceutiques comprenant ces composés et procédés de dépistage pour identifier des agents thérapeutiques |
EA016071B1 (ru) | 2005-05-13 | 2012-01-30 | Вирокем Фарма Инк. | Соединения и способы лечения или предотвращения флавивирусных инфекций |
AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
US20070004635A1 (en) * | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
WO2006130666A2 (fr) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments et procedes destines a combiner un inhibiteur de protease hcv et un competiteur akr |
AU2006252553B2 (en) | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
CN101273030B (zh) | 2005-07-29 | 2012-07-18 | 泰博特克药品有限公司 | 丙型肝炎病毒的大环抑制剂 |
PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
TWI382025B (zh) | 2005-07-29 | 2013-01-11 | Tibotec Pharm Ltd | C型肝炎病毒之大環抑制劑(四) |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JP5230417B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | C型肝炎ウイルスの大員環インヒビター |
EP1913015B1 (fr) | 2005-07-29 | 2013-12-11 | Janssen R&D Ireland | Inhibiteurs macrocycliques du virus de l'hépatite c |
DK1919898T3 (da) | 2005-07-29 | 2011-05-02 | Tibotec Pharm Ltd | Makrocykliske inhibitorer af hepatitis-C-virus |
NZ565540A (en) * | 2005-08-02 | 2011-06-30 | Vertex Pharma | Inhibitors of serine proteases |
EP2364970A1 (fr) * | 2005-08-19 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Procédés et intermédiaires |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
EP1951748B1 (fr) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Variantes du virus de l'hépatite c |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
JP3975226B2 (ja) | 2006-01-11 | 2007-09-12 | 生化学工業株式会社 | シクロアルキルカルボニルアミノ酸誘導体及びその製造方法 |
CA2636765C (fr) * | 2006-01-11 | 2014-03-18 | Seikagaku Corporation | Derive d'ester d'acide cycloalkylcarbonylamino et son procede de production |
JP4047365B2 (ja) * | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | シクロアルカンカルボキサミド誘導体及びその製造方法 |
WO2007083620A1 (fr) * | 2006-01-20 | 2007-07-26 | Kaneka Corporation | PROCÉDÉ DE PRODUCTION D'UN DÉRIVÉ DE β-AMINO-α-HYDROXYACIDE DE TYPE AMIDE |
JP5436864B2 (ja) * | 2006-02-27 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vx−950を含む共結晶体およびそれを含む医薬組成物 |
EP2007381A4 (fr) * | 2006-03-06 | 2010-11-17 | Abbott Lab | Compositions e procédés d'utilisation de ritonavir pour le traitement du virus de l'hépatite c |
EP1993994A2 (fr) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Inhibiteurs de protéase de l'hépatite c deutérés |
MX2008011869A (es) * | 2006-03-16 | 2008-12-03 | Vertex Pharma | Procedimientos e intermediarios para preparar compuestos estericos. |
EP2001497A4 (fr) | 2006-03-20 | 2012-11-07 | Vertex Pharma | Compositions pharmaceutiques |
WO2007111866A2 (fr) * | 2006-03-23 | 2007-10-04 | Schering Corporation | Combinaisons d'un ou plusieurs inhibiteurs de la protéase du vhc et d'un ou plusieurs inhibiteurs de cyp3a4, et méthodes de traitement associées |
CN101466727B (zh) | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv抑制剂及其用途 |
WO2007120595A2 (fr) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Composés organiques et leurs utilisations |
RU2419626C2 (ru) | 2006-05-23 | 2011-05-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
DE102006059317A1 (de) | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
EP1886685A1 (fr) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X |
US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
RS52874B (en) | 2006-11-15 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS |
AR064258A1 (es) | 2006-11-17 | 2009-03-25 | Tibotec Pharm Ltd | Inhibidores macrociclicos del virus de hepatitis c |
US20100081672A1 (en) | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
WO2008074035A1 (fr) | 2006-12-27 | 2008-06-19 | Abbott Laboratories | Inhibiteurs de protéase du vhc et utilisations de ceux-ci |
WO2008095058A1 (fr) * | 2007-02-01 | 2008-08-07 | Taigen Biotechnology Co. Ltd. | Inhibiteurs de la protéase du virus de l'hépatite c |
US8937080B2 (en) | 2007-02-08 | 2015-01-20 | Medivir Ab | Pyrimidine substituted macrocyclic HCV inhibitors |
EP2117537A1 (fr) | 2007-02-09 | 2009-11-18 | Irm Llc | Composés et compositions servant d'inhibiteurs de protéase d'activation de canaux |
SI2114924T1 (sl) * | 2007-02-27 | 2012-06-29 | Vertex Pharma | Ko-kristali in farmacevtski sestavki, ki jih vsebujejo |
NZ579295A (en) | 2007-02-27 | 2012-03-30 | Vertex Pharma | Inhibitors of serine proteases |
US20080255038A1 (en) * | 2007-04-11 | 2008-10-16 | Samuel Earl Hopkins | Pharmaceutical compositions |
ES2381410T3 (es) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Terapia de combinación paa el tratamiento de infecciones por VHC |
AU2008286240B2 (en) * | 2007-08-03 | 2013-05-23 | Biotron Limited | Hepatitis C antiviral compositions and methods |
CN101835774B (zh) | 2007-08-30 | 2014-09-17 | 弗特克斯药品有限公司 | 共晶体和包含该共晶体的药物组合物 |
ES2369321T3 (es) | 2007-09-14 | 2011-11-29 | Schering Corporation | Procedimiento para el tratamiento de pacientes con hepatitis c. |
US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
KR101396696B1 (ko) * | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도 |
US8106059B2 (en) | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
WO2009080836A2 (fr) | 2007-12-24 | 2009-07-02 | Tibotec Pharmaceuticals Ltd. | Indoles macrocycliques comme inhibiteurs du virus de l'hépatite c |
DE102008009761A1 (de) | 2008-02-19 | 2009-08-27 | Bayer Materialscience Ag | Verfahren zur Herstellung von Isocyanaten |
EP2101173A1 (fr) | 2008-03-14 | 2009-09-16 | Vivalis | Procédé in vitro pour déterminer si un candidat destiné à un médicament pour une protéine cible est actif contre une variante de cette protéine |
CN101580535B (zh) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
WO2010008828A2 (fr) | 2008-06-24 | 2010-01-21 | Codexis, Inc. | Procédés biocatalytiques pour la préparation de composés de proline bicycliques condensés sensiblement purs sur le plan stéréo-isomérique |
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
WO2010014744A1 (fr) * | 2008-07-29 | 2010-02-04 | The Scripps Research Institute | Inhibiteurs d'une infection par le virus de l'hépatite c |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
BRPI0922366B8 (pt) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
US8865756B2 (en) | 2008-12-03 | 2014-10-21 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
JP2012517478A (ja) | 2009-02-12 | 2012-08-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、hcv組合せ治療剤 |
US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US20100324059A1 (en) | 2009-06-23 | 2010-12-23 | Gilead Sciences, Inc. | Pharmaceutical compositions useful for treating hcv |
LT2477980T (lt) | 2009-09-15 | 2016-09-26 | Taigen Biotechnology Co., Ltd. | Hcv proteazės slopikliai |
TWI404269B (zh) * | 2009-09-18 | 2013-08-01 | Advanced Connectek Inc | High speed plug connector |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
CA2781614A1 (fr) | 2009-11-25 | 2011-06-09 | Vertex Pharmaceuticals Incorporated | Derives d'acide 5-alcynyl-thiophene-2-carboxylique et leur utilisation pour traiter ou prevenir des infections a flavivirus |
SG181797A1 (en) * | 2009-12-18 | 2012-07-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
AU2010336355A1 (en) | 2009-12-24 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
JP5833022B2 (ja) | 2010-01-27 | 2015-12-16 | エービー・ファーマ・リミテッド | C型肝炎ウィルス阻害剤としてのポリ複素環式化合物 |
CN102844030A (zh) | 2010-01-29 | 2012-12-26 | 沃泰克斯药物股份有限公司 | 用于治疗丙型肝炎病毒感染的疗法 |
WO2011112516A1 (fr) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Traitement et prévention de l'infection par le virus de l'hépatite c en utilisant des oligonucléotides antisens de la kinase c-raf |
WO2011119853A1 (fr) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues pour traiter ou prévenir les infections à flavivirus |
TW201141857A (en) | 2010-03-24 | 2011-12-01 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
TW201139438A (en) | 2010-03-24 | 2011-11-16 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
WO2011119870A1 (fr) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues pour traiter ou prévenir les infections à flavivirus |
MX2012011222A (es) | 2010-04-01 | 2013-01-18 | Centre Nat Rech Scient | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. |
EP2575866A4 (fr) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | Inhibiteurs de ns5a du vhc |
AU2011261349A1 (en) | 2010-06-03 | 2012-12-06 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
WO2011156545A1 (fr) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Modèle dynamique viral pour une polythérapie contre le vhc |
US20130157258A1 (en) | 2010-06-15 | 2013-06-20 | Vertex Pharmaceuticals Incorporated | Hcv ns5b protease mutants |
WO2012006070A1 (fr) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavivirus |
UY33473A (es) | 2010-06-28 | 2012-01-31 | Vertex Pharma | Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus |
EP2585448A1 (fr) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavovirus |
US20120014912A1 (en) | 2010-07-14 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | Palatable pharmaceutical composition |
WO2012020036A1 (fr) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Inhibiteurs du virus de l'hépatite c |
CA2808291A1 (fr) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Composes et methodes de traitement ou de prevention d'infections virales par des flaviviridae |
NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
AU2011311880B2 (en) | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
US20140308242A1 (en) | 2010-10-21 | 2014-10-16 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
CN103269586B (zh) | 2010-10-26 | 2015-07-15 | 普雷西迪奥制药公司 | 丙型肝炎病毒抑制剂 |
WO2012107589A1 (fr) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc |
WO2012109646A1 (fr) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Traitement du vhc chez des patients infectés par le vih |
WO2012123298A1 (fr) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Composés antiviraux |
WO2012154321A1 (fr) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Composés et compositions pharmaceutiques pour le traitement d'infections virales |
US8680152B2 (en) | 2011-05-02 | 2014-03-25 | Virobay, Inc. | Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain |
CN103814001A (zh) | 2011-05-13 | 2014-05-21 | 弗特克斯药品有限公司 | 方法和中间体 |
CA2857705A1 (fr) | 2011-06-16 | 2012-12-20 | AB Pharma Ltd. | Compose heterocyclique macrocyclique pour l'inhibition du virus de l'hepatite c, sa preparation et ses applications |
CN103732242A (zh) | 2011-06-23 | 2014-04-16 | 迪格纳生物技术公司 | 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎 |
WO2012175581A1 (fr) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Composés antiviraux |
WO2013016499A1 (fr) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés du thiophène |
AR087344A1 (es) | 2011-07-26 | 2014-03-19 | Vertex Pharma | Formas polimorficas del acido 5-(3,3-dimetil-but-1-inil)-3-[(trans-4-hidroxi-ciclohexil)-(trans-4-metil-ciclohexancarbonil)-amino]-tiofen-2-carboxilico y su uso en el tratamiento de la hepatitis c |
JP2014526474A (ja) | 2011-09-12 | 2014-10-06 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
WO2013049382A2 (fr) | 2011-09-27 | 2013-04-04 | Kansas State University Research Foundation | Antiviraux à large spectre contre des protéases 3c ou 3c-associées du super-groupe des picornavirus-associés : picornavirus, calicivirus et coronavirus |
CN103917541B (zh) | 2011-10-10 | 2016-08-17 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒化合物 |
ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
CN103987697B (zh) | 2011-10-14 | 2017-04-26 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
SG11201401384UA (en) | 2011-10-14 | 2014-09-26 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US8466159B2 (en) * | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
US8853176B2 (en) | 2011-10-21 | 2014-10-07 | Abbvie Inc. | Methods for treating HCV |
US9133170B2 (en) | 2011-12-16 | 2015-09-15 | Hoffmann-La Roche Inc. | Inhibitors of HCV NS5A |
CA2856179C (fr) | 2011-12-20 | 2017-02-28 | F. Hoffmann-La Roche Ag | Derives de nucleoside substitue 2',4'-difluoro-2'-methyle en tant qu'inhibiteurs de la replication de l'arn du vhc (virus de l'hepatite c) |
SI2794628T1 (sl) | 2011-12-20 | 2017-07-31 | Riboscience Llc | 4'-azido-3'-fluoro substituirani nukleozidni derivati kot inhibitorji podvojevanja RNA HCV |
US9126986B2 (en) | 2011-12-28 | 2015-09-08 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
WO2013116339A1 (fr) | 2012-01-31 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | Formulations très puissantes de vx-950 |
ITMI20120192A1 (it) | 2012-02-13 | 2013-08-14 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
EP2814807A4 (fr) * | 2012-02-16 | 2015-10-07 | Rqx Pharmaceuticals Inc | Antibiotiques à peptide linéaire |
BR112014015582A8 (pt) | 2012-02-24 | 2017-07-04 | Hoffmann La Roche | compostos antivirais |
ITMI20120359A1 (it) | 2012-03-07 | 2013-09-08 | Dipharma Francis Srl | Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali |
WO2013136265A1 (fr) | 2012-03-13 | 2013-09-19 | Dipharma Francis S.R.L. | Synthèse d'un intermédiaire d'un composé antiviral |
ITMI20120391A1 (it) * | 2012-03-13 | 2013-09-14 | Dipharma Francis Srl | Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
WO2013142157A1 (fr) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Combinaisons pharmaceutiques comprenant un analogue thionucléotidique |
EP2844249A4 (fr) | 2012-05-02 | 2016-03-09 | Univ Kansas State | Composés macrocycliques et peptidomimétiques en tant qu'antiviraux à large spectre contre des protéases 3c ou de type 3c de picornavirus, calicivirus et coronavirus |
ITMI20120800A1 (it) * | 2012-05-10 | 2013-11-11 | Dipharma Francis Srl | Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali |
CN103450066B (zh) * | 2012-05-30 | 2017-03-15 | 博瑞生物医药(苏州)股份有限公司 | 特拉匹韦中间体的制备方法 |
WO2013178682A2 (fr) | 2012-05-30 | 2013-12-05 | Chemo Ibérica, S.A. | Procédé à multicomposants pour la préparation de composés bicycliques |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
WO2014015217A1 (fr) | 2012-07-19 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Biomarqueurs pour patients infectés par le hcv |
WO2014033667A1 (fr) | 2012-08-30 | 2014-03-06 | Ranbaxy Laboratories Limited | Procédé pour la préparation de télaprévir |
WO2014045263A2 (fr) * | 2012-09-24 | 2014-03-27 | Dr. Reddy's Laboratories Limited | Procédé de préparation d'intermédiaires du télaprévir |
EP2906552B1 (fr) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Composés de tetrahydroisoquinoline substitués par guanidine en tant qu'inhibiteurs de factor xia |
WO2014059214A1 (fr) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Composés de tétrahydroisoquinoléine à substitution guanidine et amine utilisés comme inhibiteurs du facteur xia |
CN104837833B (zh) | 2012-10-12 | 2017-07-14 | 百时美施贵宝公司 | Xia因子抑制剂的晶型 |
WO2014068265A1 (fr) | 2012-10-29 | 2014-05-08 | Cipla Limited | Analogues de phosphonate antiviraux et leur procédé de préparation |
ITMI20122036A1 (it) | 2012-11-29 | 2014-05-30 | Dipharma Francis Srl | Sintesi di un intermedio di un composto antivirale |
WO2014096374A1 (fr) | 2012-12-21 | 2014-06-26 | Sandoz Ag | Procédé de synthèse de pyrrolidines et de pyrroles |
RU2015132550A (ru) | 2013-01-23 | 2017-03-02 | Ф. Хоффманн-Ля Рош Аг | Противовирусные производные триазола |
CN103113288B (zh) * | 2013-02-04 | 2015-05-20 | 苏州永健生物医药有限公司 | 一种八氢环戊烯并[c]吡咯羧酸衍生物的合成方法 |
WO2014134251A1 (fr) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques |
CA2900319A1 (fr) | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Composes antiviraux |
ES2712699T3 (es) | 2013-03-25 | 2019-05-14 | Bristol Myers Squibb Co | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa |
ITMI20130706A1 (it) | 2013-04-30 | 2014-10-31 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
EA035301B1 (ru) | 2013-05-16 | 2020-05-26 | Рибосайенс Ллк | 4'-фтор-2'-метилзамещенные нуклеозидные производные |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
US9249176B2 (en) | 2013-05-16 | 2016-02-02 | Riboscience Llc | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication |
CN104163851B (zh) * | 2013-05-20 | 2019-03-05 | 湘北威尔曼制药股份有限公司 | 氟代的α-羰基类HCV NS3/4A丝氨酸蛋白酶抑制剂 |
CN103288671B (zh) * | 2013-06-20 | 2014-10-29 | 上海步越化工科技有限公司 | 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法 |
WO2014203208A1 (fr) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Procédé pour la préparation de télaprévir et d'intermédiaires de télaprévir |
WO2014203224A1 (fr) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Procédé pour la préparation de télaprévir et d'intermédiaires de télaprévir |
CN104292146B (zh) * | 2013-06-24 | 2017-04-26 | 上海医药工业研究院 | 特拉匹韦中间体及其制备方法 |
CN104558106B (zh) * | 2013-10-19 | 2019-12-10 | 广东东阳光药业有限公司 | 一种治疗丙肝药物的制备方法 |
CN104610272B (zh) * | 2013-11-05 | 2017-03-29 | 上海唐润医药科技有限公司 | 环状黄酮或异黄酮类化合物及其用途 |
EP2899207A1 (fr) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | Nouveau procédé pour tester l'inhibition de la protéase du HCV |
NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
CN116987080A (zh) | 2014-01-31 | 2023-11-03 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
CN104926831A (zh) * | 2014-03-20 | 2015-09-23 | 上海医药工业研究院 | 合成特拉匹韦的中间体及其制备方法 |
CN104926712B (zh) * | 2014-03-20 | 2018-03-23 | 上海医药工业研究院 | 合成特拉匹韦的中间体及其制备方法 |
MX2016015593A (es) | 2014-07-07 | 2017-06-26 | Halliburton Energy Services Inc | Herramientas del interior del pozo que comprenden elementos de cierre hermetico degradables en fluido acuoso. |
JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fxia阻害剤であるジアミドマクロ環 |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
CN108699106B (zh) | 2016-03-04 | 2021-11-30 | 豪夫迈·罗氏有限公司 | 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物 |
WO2017148967A1 (fr) | 2016-03-04 | 2017-09-08 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de difluorocétamide utilisés en tant qu'inhibiteurs de htra1 |
WO2017189978A1 (fr) | 2016-04-28 | 2017-11-02 | Emory University | Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées |
MX2018016102A (es) | 2016-06-21 | 2019-08-29 | Orion Ophthalmology LLC | Derivados alifaticos de prolinamida. |
WO2017222915A1 (fr) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Dérivés hétérocycliques de prolinamide |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
JP2019526563A (ja) * | 2016-08-23 | 2019-09-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Htra1阻害剤としての新規ジフルオロケタミド誘導体 |
EP3684374A4 (fr) | 2017-09-21 | 2021-06-16 | Riboscience LLC | Dérivés nucléosidiques à substitution 4'-fluoro-2'-méthyle utilisés comme inhibiteurs de la réplication de l'arn du vhc |
CN109337537B (zh) * | 2018-09-26 | 2022-10-25 | 河北晨阳工贸集团有限公司 | 一种起重机专用单组分水性面漆及其制备方法 |
CN110668538B (zh) * | 2019-09-20 | 2021-10-22 | 济南大学 | 一种聚合氯化钛的制备方法 |
CN114057702B (zh) * | 2020-07-31 | 2022-09-30 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
CN115960088A (zh) * | 2020-07-31 | 2023-04-14 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
WO2023149981A1 (fr) * | 2022-02-07 | 2023-08-10 | Purdue Research Foundation | Composés pour le traitement du sars |
CN114703003B (zh) * | 2022-04-14 | 2023-04-28 | 上海绿晟环保科技有限公司 | 一种负载碳量子点的纳米材料润滑添加剂及其制备方法 |
CN115417790A (zh) * | 2022-10-09 | 2022-12-02 | 山东大学 | 一类新型偶氮类发泡剂及合成方法 |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
DE3211676A1 (de) | 1982-03-30 | 1983-10-06 | Hoechst Ag | Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
FR2570695A1 (fr) * | 1984-09-27 | 1986-03-28 | Synthelabo | Diphenylazomethines a chaine ramifiee ou cyclique, leur preparation et leur application en therapeutique |
FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5496927A (en) | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
DE3683541D1 (de) * | 1985-06-07 | 1992-03-05 | Ici America Inc | Selektionierte difluorverbindungen. |
US4835168A (en) | 1985-12-16 | 1989-05-30 | Eli Lilly And Company | Thiadiazole antiviral agents |
US5231084A (en) | 1986-03-27 | 1993-07-27 | Hoechst Aktiengesellschaft | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons |
US5736520A (en) | 1988-10-07 | 1998-04-07 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
NZ235155A (en) | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
US5371072A (en) * | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
DE69329544T2 (de) | 1992-12-22 | 2001-05-31 | Lilly Co Eli | HIV Protease hemmende Verbindungen |
KR100360964B1 (ko) | 1992-12-29 | 2002-11-22 | 아보트 러보러터리즈 | 레트로바이러스성 프로테아제 억제 화합물의 중간체의제조방법 |
US5384410A (en) | 1993-03-24 | 1995-01-24 | The Du Pont Merck Pharmaceutical Company | Removal of boronic acid protecting groups by transesterification |
US5656600A (en) * | 1993-03-25 | 1997-08-12 | Corvas International, Inc. | α-ketoamide derivatives as inhibitors of thrombosis |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
IL113196A0 (en) | 1994-03-31 | 1995-06-29 | Bristol Myers Squibb Co | Imidazole derivatives and pharmaceutical compositions containing the same |
US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5861267A (en) * | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
JPH09124691A (ja) * | 1995-08-25 | 1997-05-13 | Green Cross Corp:The | ペプチド化合物およびそれを含有する医薬組成物 |
EP1019410A1 (fr) | 1995-11-23 | 2000-07-19 | MERCK SHARP & DOHME LTD. | Derives de spiro-piperidine et leur utilisation en tant qu'antagonistes de tachykinine |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
US6127422A (en) | 1996-05-06 | 2000-10-03 | Eli Lilly And Company | Anti-viral method |
CA2254122A1 (fr) | 1996-05-10 | 1997-11-20 | Schering Corporation | Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
WO1997043319A1 (fr) | 1996-05-17 | 1997-11-20 | Datacard Corporation | Composition de couche de finition polymerisable et procedes d'utilisation |
EP0913389A4 (fr) * | 1996-06-28 | 2000-02-02 | Nippon Chemiphar Co | Derives de cyclopropylglycine et agoniste du recepteur du l-glutamate du type a regulation metabolique |
US6245919B1 (en) * | 1996-06-28 | 2001-06-12 | Haruhiko Shinozaki | Cyclopropylglycine derivatives and agonists for metabotronic L-glutamate receptors |
US6153579A (en) * | 1996-09-12 | 2000-11-28 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
WO1998013369A1 (fr) | 1996-09-25 | 1998-04-02 | Merck Sharp & Dohme Limited | Derives spiro-azacycliques, preparation de ces derives et leur utilisation comme antagonistes de la tachykinine |
ES2207721T3 (es) | 1996-10-08 | 2004-06-01 | Colorado State University Research Foundation | Epoxidacion catalitica asimetrica. |
BR9712544B1 (pt) * | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
DE19648011A1 (de) | 1996-11-20 | 1998-05-28 | Bayer Ag | Cyclische Imine |
EP0966465B1 (fr) | 1997-03-14 | 2003-07-09 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de l'enzyme impdh |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
GB9708484D0 (en) | 1997-04-25 | 1997-06-18 | Merck Sharp & Dohme | Therapeutic agents |
GB9711114D0 (en) | 1997-05-29 | 1997-07-23 | Merck Sharp & Dohme | Therapeutic agents |
AU757783B2 (en) | 1997-08-11 | 2003-03-06 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
EP1012180B1 (fr) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Analogues de peptides inhibiteurs de l'hepatite c |
US6183121B1 (en) * | 1997-08-14 | 2001-02-06 | Vertex Pharmaceuticals Inc. | Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets |
US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
WO1999028482A2 (fr) | 1997-11-28 | 1999-06-10 | Schering Corporation | Complexes recombinants monocatenaires de la protease ns3 et du peptide co-facteur ns4a du virus de l'hepatite c (vhc) |
WO1999050230A1 (fr) | 1998-03-31 | 1999-10-07 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de serine protease, particulierement de la protease ns3 du virus de l'hepatite c |
US6518305B1 (en) * | 1998-04-23 | 2003-02-11 | Abbott Laboratories | Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases |
US6251583B1 (en) | 1998-04-27 | 2001-06-26 | Schering Corporation | Peptide substrates for HCV NS3 protease assays |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
AR022061A1 (es) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
US6117639A (en) * | 1998-08-31 | 2000-09-12 | Vertex Pharmaceuticals Incorporated | Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity |
US6025516A (en) | 1998-10-14 | 2000-02-15 | Chiragene, Inc. | Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes |
ES2306646T3 (es) | 1999-02-09 | 2008-11-16 | Pfizer Products Inc. | Composiciones de farmacos basicos con biodisponibilidad incrementada. |
US20020042046A1 (en) | 1999-02-25 | 2002-04-11 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
EE200100492A (et) | 1999-03-19 | 2002-12-16 | Vertex Pharmaceuticals Incorporated | Ensüümi IMPDH inhibiitorid |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
US20020183249A1 (en) | 1999-08-31 | 2002-12-05 | Taylor Neil R. | Method of identifying inhibitors of CDC25 |
US6774212B2 (en) | 1999-12-03 | 2004-08-10 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
US6365380B2 (en) * | 2000-02-23 | 2002-04-02 | Pcbu Services, Inc. | Method for stereoselectively inverting a chiral center of a chemical compound using an enzyme and a metal catalyst |
WO2001064678A2 (fr) | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Pharma Company | Inhibiteurs de la protéase ns3 du virus de l'hépatite c |
IL152022A0 (en) * | 2000-04-03 | 2003-04-10 | Vertex Pharma | Compounds useful as protease inhibitors and pharmaceutical compositions containing the same |
EP1268525B1 (fr) | 2000-04-05 | 2008-12-31 | Schering Corporation | Inhibiteurs macrocycliques de la protease a serine ns3 du virus de l'hepatite c, comprenant des fragments p2 n- cycliques |
AR030558A1 (es) | 2000-04-19 | 2003-08-27 | Schering Corp | COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA, |
CA2414960C (fr) | 2000-06-30 | 2012-04-10 | Seikagaku Corporation | Amides d'acide carboxylique, azides et amino-alcools et procedes de preparation de .alpha-ceto amides a l'aide de ces derniers |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
RU2003105221A (ru) | 2000-07-21 | 2004-09-20 | Шеринг Корпорейшн (US) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с |
AU2001276988B2 (en) | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
EP1301527A2 (fr) | 2000-07-21 | 2003-04-16 | Corvas International, Inc. | Nouveaux peptides utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6939692B2 (en) | 2000-09-12 | 2005-09-06 | Degussa Ag | Nucleotide sequences coding for the pknB gene |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
BR0115447A (pt) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
WO2002048172A2 (fr) | 2000-12-12 | 2002-06-20 | Schering Corporation | Peptides diaryliques utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
US6727366B2 (en) | 2000-12-13 | 2004-04-27 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors |
RS50236B (sr) | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze |
GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
CA2436518A1 (fr) * | 2001-01-30 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | Detection quantitative d'acides nucleiques |
JP4499990B2 (ja) * | 2001-03-27 | 2010-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Hcv感染に有用な組成物および方法 |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
JP2005500322A (ja) | 2001-07-03 | 2005-01-06 | アルタナ ファルマ アクチエンゲゼルシャフト | 3−フェニルイソセリンの製法 |
NZ530000A (en) * | 2001-07-11 | 2007-03-30 | Vertex Pharma | Peptidomimetic bridged bicyclic serine protease inhibitors |
US7029561B2 (en) | 2001-07-25 | 2006-04-18 | The United States Of America As Represented By The Secretary Of Commerce | Fluidic temperature gradient focusing |
JP2003055389A (ja) | 2001-08-09 | 2003-02-26 | Univ Tokyo | 錯体及びそれを用いたエポキシドの製法 |
US6824769B2 (en) * | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
MXPA04003825A (es) * | 2001-10-24 | 2004-07-08 | Vertex Pharma | Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado. |
CA2672549A1 (fr) | 2001-11-14 | 2003-06-12 | Ben-Zion Dolitzky | Formes cristallines amorphes de losartan potassique et leur procede de preparation |
CA2369711A1 (fr) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Peptides macrocycliques qui agissent contre le virus de l'hepatite c |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2369970A1 (fr) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Tri-peptides inhibiteur de l'hepatite c |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
WO2003087092A2 (fr) * | 2002-04-11 | 2003-10-23 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c |
JP2006507235A (ja) | 2002-08-01 | 2006-03-02 | フアーマセツト・インコーポレイテツド | フラビウイルス科ウイルス感染治療のためのビシクロ[4.2.1]ノナン系を有する化合物 |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
CA2413705A1 (fr) | 2002-12-06 | 2004-06-06 | Raul Altman | Utilisation de meloxicame avec un agent antiplaquettaire pour le traitement du syndrome coronarien aigu et de troubles connexes |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
JP2006517960A (ja) | 2003-02-18 | 2006-08-03 | ファイザー インコーポレイテッド | C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法 |
CA2516016C (fr) | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Composes d'inhibition de l'hepatite c |
DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
WO2004092162A1 (fr) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc |
WO2004092161A1 (fr) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc |
CN1791599A (zh) | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
UY28423A1 (es) * | 2003-07-18 | 2005-02-28 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- |
WO2005018330A1 (fr) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Regime de dosage pour therapie contre flaviviridae |
MY148123A (en) * | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
AU2004272114B2 (en) * | 2003-09-12 | 2010-11-04 | Vertex Pharmaceuticals Incorporated | Animal model for protease activity and liver damage |
TW200526686A (en) * | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US6933760B2 (en) | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
CA2536182C (fr) | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Peptides macrocycliques actifs contre le virus de l'hepatite c |
KR20060130027A (ko) * | 2003-10-10 | 2006-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의억제제 |
AR045870A1 (es) * | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
US7494660B2 (en) | 2003-10-27 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
MXPA06004723A (es) * | 2003-10-27 | 2006-07-05 | Vertex Pharma | Combinacion para el tratamiento del hcv. |
WO2005043118A2 (fr) * | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Methode de decouverte de medicament |
EP1678134B1 (fr) * | 2003-10-28 | 2009-09-09 | Vertex Pharmaceuticals Incorporated | Preparation de derives d'acide 4,5-dialkyl-3-acyl-pyrrole-2-carboxylique au moyen d'une synthese de type fischer-fink et d'une acylation subsequente |
US20050119318A1 (en) | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1689857A1 (fr) * | 2003-12-01 | 2006-08-16 | Vertex Pharmaceuticals Incorporated | Compositions renfermant des cellules hepatiques foetales, et procedes utiles pour le traitement de l'infection par le vhc |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
AU2005212257A1 (en) * | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
EP1718608B1 (fr) | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Inhibiteurs de la polymerase virale |
US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
WO2005087730A1 (fr) | 2004-02-27 | 2005-09-22 | Schering Corporation | Composes de proline fusionnes a 3,4-(cyclopentyl) en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c |
SI2399915T1 (sl) * | 2004-03-12 | 2015-05-29 | Vertex Pharmaceuticals Incorporated | Postopek in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze |
AR049635A1 (es) | 2004-05-06 | 2006-08-23 | Schering Corp | (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c |
US20060089385A1 (en) * | 2004-06-08 | 2006-04-27 | Yong Cui | Pharmaceutical compositions |
WO2006026352A1 (fr) | 2004-08-27 | 2006-03-09 | Schering Corporation | Composes d'acylsulfonamide inhibiteurs de la serine protease ns3 du virus de l'hepatite c |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
NZ565540A (en) * | 2005-08-02 | 2011-06-30 | Vertex Pharma | Inhibitors of serine proteases |
EP2364970A1 (fr) * | 2005-08-19 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Procédés et intermédiaires |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
JP5436864B2 (ja) * | 2006-02-27 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vx−950を含む共結晶体およびそれを含む医薬組成物 |
MX2008011869A (es) * | 2006-03-16 | 2008-12-03 | Vertex Pharma | Procedimientos e intermediarios para preparar compuestos estericos. |
EP1993994A2 (fr) * | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Inhibiteurs de protéase de l'hépatite c deutérés |
EP2001497A4 (fr) | 2006-03-20 | 2012-11-07 | Vertex Pharma | Compositions pharmaceutiques |
TW200812611A (en) * | 2006-03-20 | 2008-03-16 | Vertex Pharma | Pharmaceutical compositions |
RU2446800C2 (ru) * | 2006-05-31 | 2012-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Препаративные формы с контролируемым высвобождением |
NZ579295A (en) | 2007-02-27 | 2012-03-30 | Vertex Pharma | Inhibitors of serine proteases |
-
2001
- 2001-08-30 SV SV2001000617A patent/SV2003000617A/es not_active Application Discontinuation
- 2001-08-31 CN CN2009101474875A patent/CN101633636B/zh not_active Expired - Fee Related
- 2001-08-31 KR KR1020087025504A patent/KR20080104383A/ko not_active Application Discontinuation
- 2001-08-31 KR KR1020037002880A patent/KR100876472B1/ko not_active IP Right Cessation
- 2001-08-31 CN CN2013100240570A patent/CN103232381A/zh active Pending
- 2001-08-31 AU AU2001288318A patent/AU2001288318B2/en not_active Ceased
- 2001-08-31 TW TW099107489A patent/TWI378927B/zh not_active IP Right Cessation
- 2001-08-31 EP EP20100185155 patent/EP2368901A1/fr not_active Withdrawn
- 2001-08-31 AT AT01968040T patent/ATE431358T1/de active
- 2001-08-31 EP EP07012485A patent/EP1878720B1/fr not_active Expired - Lifetime
- 2001-08-31 BR BR0113666-6A patent/BR0113666A/pt not_active IP Right Cessation
- 2001-08-31 ES ES10185132.7T patent/ES2489115T3/es not_active Expired - Lifetime
- 2001-08-31 CA CA2419607A patent/CA2419607C/fr not_active Expired - Fee Related
- 2001-08-31 EP EP01968040A patent/EP1320540B9/fr not_active Expired - Lifetime
- 2001-08-31 AR ARP010104168A patent/AR030591A1/es active IP Right Grant
- 2001-08-31 AT AT07012485T patent/ATE483686T1/de not_active IP Right Cessation
- 2001-08-31 TW TW097127487A patent/TWI339661B/zh not_active IP Right Cessation
- 2001-08-31 ES ES01968040T patent/ES2325481T3/es not_active Expired - Lifetime
- 2001-08-31 ES ES07012485T patent/ES2352804T3/es not_active Expired - Lifetime
- 2001-08-31 KR KR1020087025505A patent/KR20080104384A/ko not_active Application Discontinuation
- 2001-08-31 ES ES07012483.9T patent/ES2450815T3/es not_active Expired - Lifetime
- 2001-08-31 CA CA2697205A patent/CA2697205C/fr not_active Expired - Fee Related
- 2001-08-31 JP JP2002523884A patent/JP4689938B2/ja not_active Expired - Lifetime
- 2001-08-31 EP EP10185132.7A patent/EP2368877B1/fr not_active Expired - Lifetime
- 2001-08-31 CN CN200910149350.3A patent/CN101693672B/zh not_active Expired - Fee Related
- 2001-08-31 KR KR1020117015737A patent/KR20110088600A/ko not_active Application Discontinuation
- 2001-08-31 AU AU8831801A patent/AU8831801A/xx active Pending
- 2001-08-31 TW TW099107488A patent/TWI359144B/zh not_active IP Right Cessation
- 2001-08-31 KR KR1020107007135A patent/KR20100043293A/ko not_active Application Discontinuation
- 2001-08-31 CN CN2006100803265A patent/CN1869061B/zh not_active Expired - Fee Related
- 2001-08-31 DE DE20122915U patent/DE20122915U1/de not_active Expired - Lifetime
- 2001-08-31 PT PT01968040T patent/PT1320540E/pt unknown
- 2001-08-31 US US10/344,112 patent/US7820671B2/en not_active Expired - Fee Related
- 2001-08-31 EA EA200300318A patent/EA011547B1/ru not_active IP Right Cessation
- 2001-08-31 UA UA2003021834A patent/UA81600C2/uk unknown
- 2001-08-31 KR KR1020087025506A patent/KR20080096718A/ko not_active Application Discontinuation
- 2001-08-31 DK DK07012485.4T patent/DK1878720T3/da active
- 2001-08-31 DK DK01968040.4T patent/DK1320540T5/da active
- 2001-08-31 NZ NZ541302A patent/NZ541302A/en not_active IP Right Cessation
- 2001-08-31 NZ NZ569670A patent/NZ569670A/en not_active IP Right Cessation
- 2001-08-31 IL IL15467101A patent/IL154671A0/xx unknown
- 2001-08-31 PL PL365836A patent/PL211019B1/pl unknown
- 2001-08-31 KR KR1020097022810A patent/KR20090120013A/ko not_active Application Discontinuation
- 2001-08-31 EP EP07111000A patent/EP1849797A3/fr not_active Withdrawn
- 2001-08-31 CN CN2011103464269A patent/CN102504014A/zh active Pending
- 2001-08-31 KR KR1020087025503A patent/KR100968295B1/ko not_active IP Right Cessation
- 2001-08-31 CN CN200910149349A patent/CN101696232A/zh active Pending
- 2001-08-31 TW TW090121629A patent/TWI319763B/zh not_active IP Right Cessation
- 2001-08-31 CZ CZ2003595A patent/CZ2003595A3/cs unknown
- 2001-08-31 HU HU0300855A patent/HUP0300855A3/hu unknown
- 2001-08-31 TW TW099107492A patent/TWI359145B/zh not_active IP Right Cessation
- 2001-08-31 UA UAA200710133A patent/UA99895C2/uk unknown
- 2001-08-31 PE PE2001000876A patent/PE20020474A1/es active IP Right Grant
- 2001-08-31 DE DE60143233T patent/DE60143233D1/de not_active Expired - Lifetime
- 2001-08-31 WO PCT/US2001/026008 patent/WO2002018369A2/fr active Application Filing
- 2001-08-31 TW TW099107493A patent/TW201022244A/zh unknown
- 2001-08-31 EP EP07012483.9A patent/EP1958956B1/fr not_active Expired - Lifetime
- 2001-08-31 SK SK249-2003A patent/SK2492003A3/sk unknown
- 2001-08-31 DZ DZ013438A patent/DZ3438A1/fr active
- 2001-08-31 EA EA200701869A patent/EA017556B1/ru not_active IP Right Cessation
- 2001-08-31 EP EP10185722A patent/EP2371839A1/fr not_active Withdrawn
- 2001-08-31 KR KR1020077029814A patent/KR100945975B1/ko not_active IP Right Cessation
- 2001-08-31 EP EP07012484A patent/EP1876173A1/fr not_active Withdrawn
- 2001-08-31 KR KR1020107007138A patent/KR20100042296A/ko active Application Filing
- 2001-08-31 SI SI200130924T patent/SI1320540T1/sl unknown
- 2001-08-31 CN CNB018150551A patent/CN100522991C/zh not_active Expired - Fee Related
- 2001-08-31 DE DE60138717T patent/DE60138717D1/de not_active Expired - Lifetime
- 2001-08-31 EP EP10185148A patent/EP2368878A1/fr not_active Withdrawn
- 2001-08-31 MX MXPA03001780A patent/MXPA03001780A/es active IP Right Grant
-
2003
- 2003-02-25 EC EC2003004493A patent/ECSP034493A/es unknown
- 2003-02-25 HR HRP20030139AA patent/HRP20030139B8/hr not_active IP Right Cessation
- 2003-02-27 IL IL154671A patent/IL154671A/en not_active IP Right Cessation
- 2003-02-27 NO NO20030928A patent/NO329929B1/no not_active IP Right Cessation
- 2003-02-27 ZA ZA200301641A patent/ZA200301641B/en unknown
- 2003-11-19 HK HK12103079.4A patent/HK1163061A1/xx not_active IP Right Cessation
- 2003-11-19 HK HK08104142.1A patent/HK1114090A1/xx not_active IP Right Cessation
- 2003-11-19 HK HK03108422.8A patent/HK1057758A1/xx not_active IP Right Cessation
-
2007
- 2007-01-31 EC EC2007007217A patent/ECSP077217A/es unknown
- 2007-05-30 JP JP2007143124A patent/JP2007284444A/ja active Pending
- 2007-08-30 IL IL185644A patent/IL185644A0/en unknown
-
2008
- 2008-09-08 US US12/231,982 patent/US8252923B2/en not_active Expired - Fee Related
-
2009
- 2009-07-20 CY CY20091100765T patent/CY1109216T1/el unknown
-
2010
- 2010-01-18 NO NO20100093A patent/NO20100093L/no not_active Application Discontinuation
- 2010-04-07 CL CL2010000330A patent/CL2010000330A1/es unknown
- 2010-07-12 NO NO20100999A patent/NO330807B1/no not_active IP Right Cessation
- 2010-10-25 JP JP2010238165A patent/JP5269035B2/ja not_active Expired - Fee Related
-
2011
- 2011-10-24 IL IL215890A patent/IL215890A0/en unknown
- 2011-10-24 IL IL215892A patent/IL215892A/en not_active IP Right Cessation
- 2011-10-24 IL IL215891A patent/IL215891A/en not_active IP Right Cessation
- 2011-11-10 US US13/293,812 patent/US20120064034A1/en not_active Abandoned
-
2012
- 2012-03-19 LU LU91960C patent/LU91960I2/fr unknown
- 2012-03-19 CY CY2012007C patent/CY2012007I2/el unknown
- 2012-03-19 DE DE201212000015 patent/DE122012000015I1/de active Pending
- 2012-04-03 NO NO2012006C patent/NO2012006I1/no unknown
- 2012-05-28 JP JP2012120678A patent/JP2012197289A/ja active Pending
- 2012-07-03 US US13/541,436 patent/US8529882B2/en not_active Expired - Fee Related
-
2014
- 2014-06-17 US US14/306,778 patent/US20140294763A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ3438A1 (fr) | Inhibiteurs peptidomimetiques de protease | |
NO20012980D0 (no) | Proteaseinhibitorer | |
AP2002002593A0 (en) | Protease inhibitors | |
ATE325091T1 (de) | Aspartyl-protease inhibitoren | |
DK1272488T3 (da) | Tri-aryl-substitueret ethan-PDE4-inhibitorer | |
NO20025786D0 (no) | Protaseinhibitorer | |
NO20025005L (no) | Proteaseinhibitorer | |
NO20025281D0 (no) | Peptid-deformylase-inhibitorer | |
NO20032328L (no) | Proteaseinhibitorer | |
AR028075A1 (es) | Inhibidores de la peptido-desformilasa | |
DOP2001000307A (es) | Inhibidores de thrombin |